▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Dan Carroll

TMFCane

Dan began writing for the Motley Fool in 2012. He is a health care specialist who also follows the defense industry along with tracking the broader U.S. and international markets.

Recent Articles by Dan Carroll

Jan 17, 2014 by Dan Carroll

Is This Big Pharma Giant Headed for Another Breakup?

Generic drugmakers Actavis, Valeant, and Mylan are all reportedly interested in Pfizer's generic drug business. Will Pfizer play ball and sell off yet another one of its slower-growth units?

Jan 17, 2014 by Dan Carroll

American Express Booms to Lead the Dow Past GE and Intel's Fall

American Express and Visa lead the Dow higher on a day when most of the index has fallen into the red.

Jan 17, 2014 by Dan Carroll

Has This Hot Med Tech Market Frozen Over?

Renal denervation's a huge opportunity for Medtronic, St. Jude Medical, and other leading device companies, but recent setbacks have investors wondering how long it will be before potential translates into results

Jan 16, 2014 by Dan Carroll

Despite Strong Earnings, UnitedHealth and Goldman Sachs Take Down the Dow

UnitedHealth and Goldman Sachs rank as the top blue-chip laggards on the day, with investors in the insurer in particular overlooking strong fourth-quarter earnings to worry about future results

Jan 15, 2014 by Dan Carroll

This Health Care Giant's Biggest Opportunity Isn't in America

Here's how Covidien's latest buys highlight the huge opportunities abroad that Stryker, Medtronic, and other device firms are racing to take advantage of.

Jan 15, 2014 by Dan Carroll

Banking's Boom Keeps the Dow On Track for 100-Point Gain

JPMorgan and other bank stocks surge behind great results from Bank of America, while Microsoft leads tech stocks higher on a good day for blue-chip investors

Jan 14, 2014 by Dan Carroll

JPMorgan Profits Slide as the Dow Bounces Higher

Intel leads the Dow's charge into the green despite a sluggish day from JPMorgan's stock following the bank's earnings release

Jan 13, 2014 by Dan Carroll

Merck's Boom Outshines the Dow's 100-Point Plunge

Merck lights up the markets with an early drug filing as Disney and other top blue-chip stocks lead the markets down.

Jan 11, 2014 by Dan Carroll

AstraZeneca plc (ADR): 1 Struggling Big Pharma Hoping to Hit the Acquisitions Jackpot

AstraZeneca's floundering under falling sales and looming patent expirations, but the firm's hoping to beef up its pipeline through acquisitions -- and South Korea's biologic developer Celltrion offers up a tempting target.

Jan 10, 2014 by Dan Carroll

Will Cardiac Device Stocks Have a Pulse in 2014?

Boston Scientific, St. Jude Medical, and Medtronic put on a show for investors in 2013, but can they keep up their momentum in the new year?

Jan 10, 2014 by Dan Carroll

Are Merck & Co., Inc. and Novartis AG (ADR) a Match Made in Health Care Heaven?

Novartis is considering divesting its animal health business, but could a swap for Merck's consumer unit be the best option for this big pharma firm?

Jan 10, 2014 by Dan Carroll

Painfully Slow Jobs Growth Drags Down the Dow

Jobs posted their slowest monthly growth in three years, while Chevron and Pfizer are among the Dow's top losers today

Jan 10, 2014 by Dan Carroll

3 Reasons to Buy Abbott Laboratories in 2014

Abbott Labs hasn't slowed down in its post-pharmaceutical life, but 2014 brings reasons for investors to believe in this sturdy stock.

Jan 9, 2014 by Dan Carroll

Verizon, AT&T Lag as the Dow Hits a Snag

Telecoms fall, while JPMorgan Chase declines after weighing a potential divestment of its prepaid card business.

Jan 8, 2014 by Dan Carroll

Mulally's Rejection Sparks Microsoft's Fall as the Dow Dives

Microsoft shares tumble as the company's CEO hunt goes on, while Boeing rises behind yet another strong sale.

Jan 8, 2014 by Dan Carroll

Has Sony's PlayStation 4 One-Upped Microsoft and the Xbox One?

Sony's unveiling of streaming service PlayStation Now puts the pressure on Microsoft in the fight for video gaming dominance.

Jan 8, 2014 by Dan Carroll

Can 2014's Riskiest Big Pharma Stock Launch a Comeback?

Eli Lilly missed the 2013 rally that propelled big pharma stocks like Pfizer and AstraZeneca. Can this company beat the patent cliff in the long term and turn things around for disappointed investors?

Jan 7, 2014 by Dan Carroll

UnitedHealth and Johnson & Johnson Upgrades Lead the Dow's Rally

Johnson & Johnson and UnitedHealth surge to the top of the blue-chip leaderboard on a day of strong gains across the markets.

Jan 6, 2014 by Dan Carroll

Microsoft's Fall Drags Down the Dow

Despite seeing strong sales of its Xbox One console, Microsoft fails to make a dent on the markets today with a big loss.

Jan 3, 2014 by Dan Carroll

Are Health Care Investors Facing a China Catastrophe?

As Beijing looks to create its health care blacklist, companies can ill afford to find themselves in the midst of a scandal like the one that plagued GlaxoSmithKline in 2013.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services